KRAS
Most common oncogenic driver across solid tumors. KRAS G12C now targetable with sotorasib and adagrasib.
No Clinical Trials found for this biomarker.
Most common oncogenic driver across solid tumors. KRAS G12C now targetable with sotorasib and adagrasib.
No Clinical Trials found for this biomarker.